Literature DB >> 18161645

Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia.

Stéphane Potvin1, Emmanuel Stip, Olivier Lipp, Marc-André Roy, Marie-France Demers, Roch-Hugo Bouchard, Alain Gendron.   

Abstract

The current study sought to identify the variables, derived from the self-medication hypothesis, which predicted substance abuse evolution during a homogeneous 3-month antipsychotic treatment. Twenty-four patients were diagnosed with schizophrenia and substance abuse (mainly cannabis and alcohol). Substance abuse, psychiatric symptoms, anhedonia, and social adjustment were assessed at baseline and study endpoint. Linear regression analyses were performed. Better social adaptation and worse anhedonia predicted substance abuse improvements. Conversely, greater psychoactive substance (PAS) use predicted endpoint positive and depressive symptoms. These results suggest that: (i) substance abuse interferes with psychiatric prognosis in schizophrenia; and (ii) dual diagnosis treatments leading patients to engage in alternative social activities may render substance abuse less appealing. Further studies are warranted to dissociate the causes and consequences of substance abuse in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18161645     DOI: 10.1080/00952990701764631

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  8 in total

Review 1.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia.

Authors:  Valéria de Almeida; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-01       Impact factor: 5.270

Review 2.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

3.  Antipsychotic treatment of adolescent dual diagnosis patients.

Authors:  Scott A Price; Nancy C Brahm
Journal:  J Pediatr Pharmacol Ther       Date:  2011-10

4.  Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia.

Authors:  Giuliana S Zuccoli; Caroline Brandão-Teles; Gabriela Maciel Vieira; Felipe V Gomes; Fernanda Crunfli
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

5.  Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.

Authors:  Pierre-Michel Llorca; Philippe Nuss; Éric Fakra; Isabelle Alamome; Dominique Drapier; Wissam El Hage; Renaud Jardri; Stéphane Mouchabac; Marc Rabbani; Nicolas Simon; Marie-Noëlle Vacheron; Jean-Michel Azorin
Journal:  BMC Psychiatry       Date:  2022-05-28       Impact factor: 4.144

6.  Denial and acceptance coping styles and medication adherence in schizophrenia.

Authors:  Stephanie Aldebot; Amy G Weisman de Mamani
Journal:  J Nerv Ment Dis       Date:  2009-08       Impact factor: 2.254

7.  Reasons for illicit drug use in people with schizophrenia: Qualitative study.

Authors:  Carolyn J Asher; Linda Gask
Journal:  BMC Psychiatry       Date:  2010-11-22       Impact factor: 3.630

8.  Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments?

Authors:  Emilie Paul-Savoie; Serge Marchand; Mélanie Morin; Patricia Bourgault; Nathalie Brissette; Vongmaly Rattanavong; Christian Cloutier; Alain Bissonnette; Stéphane Potvin
Journal:  Open Rheumatol J       Date:  2012-10-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.